@article{b274d8a0ab4811ddb5e9000ea68e967b,
title = "Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.",
abstract = "Takeda San Diego Inc is developing alogliptin, a small-molecule, orally available dipeptidyl peptidase IV (DPP IV) inhibitor, for the potential treatment of type 2 diabetes. In January 2008, Takeda announced that an NDA for alogliptin had been submitted to the FDA.",
author = "Deacon, {Carolyn F}",
note = "Keywords: Animals; Antigens, CD26; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Interactions; Humans; Hypoglycemic Agents; Molecular Structure; Patents as Topic; Piperidines; Structure-Activity Relationship; Treatment Outcome; Uracil",
year = "2008",
language = "English",
volume = "9",
pages = "402--13",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor & Francis",
number = "4",
}
